Approved Study Database

Ref. No. Scientific Title Principal investigator
2013.115 An Open Label, Phase 2a, Single-Arm Study of the Antifibrotic Activity of FG-3019 in Subjects with Advanced Liver Fibrosis due to Chronic Hepatitis C Infection (HCV) Prof Chan Lik Yuen Henry
2013.117 An Open Label, Phase 2a, Single-Arm Study of the Antifibrotic Activity of FG-3019 in Subjects with Advanced Liver Fibrosis due to Chronic Hepatitis C Infection (HCV) Dr. Hui Aric Josun
2022.174 AN OPEN LABEL, RANDOMISED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MTL-CEBPA ADMINISTERED IN COMBINATION WITH SORAFENIB OR SORAFENIB ALONE, IN TKI NAÏVE PARTICIPANTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) AND HEPATITIS B OR HEPATITIS C VIRUS (OUTREACH2) Prof. CHAN Stephen Lam
陳林
2014.409 An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) Prof. CHAN Anthony Tak Cheung
2010.600 An Open Label, Randomized, Cross-Over Study to Investigate the Single Dose Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg) Compared to Lamotrigine Compressed/Standard Tablets (25mg) in Chinese Healthy Male Subjects. Professor Tomlinson Brian
2007.038 An Open Label, Randomized, Multi-Center, Parallel Group Study to Demonstrate Treatment of Anemia Using Intravenous Injections of RO0503821 in Patients with Chronic Kidney Disease Who are on Dialysis Dr. Li KT Philip
2003.190 An Open Label, Randomized, Multicenter, Phase II Study to Determine Hemoglobin Dose Response, Safety and Pharmacokinetic Profile of Ro 50-3821 Given Subcutaneously Once Weekly or Once Every 3 Weeks to Anemic Patients with Stage IIIB or IV Non-Small Cell Lung Carcinoma Receiving Antineoplastic Therapy Prof. Mok S.K. Tony
2005.415 An Open Label, Randomized, Parallel Group, Multicentre, Phase III Study to Assess Efficacy, Safety and Tolerability of Gefitinib (IRESSA Prof. Mok SK Tony
2018.362 An open uncontrolled trial of Imagery Rescripting for Depression Ms. LEE Sze Wai
李思慧
2004.371 An Open-Label 7-Day Study to Determine the Influence of CYP2C19 Genotype on the Pharmacokinetics of RO2052349 in Patients with Type 2 Diabetes Mellitus in the Asia-Pacific Region Prof. Brian Tomlinson
2013.430 AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 Dr. WONG Raymond Siu Ming
2007.371 An Open-Label Clinical Trial to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (PEGASYS_) Plus Entecavir (Baraclude) combination Therapy in HBeAg Positive Chronic Hepatitis B (CHB) Patients Prof. Sung JY Joseph
2006.367 An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer Dr. Ho Wing Ming
2008.382 An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures Dr Kwan Patrick
2003.293 An Open-Label Extension Study to Assess the Safety and Tolerability of a 25mg Dose of SCH 420814 as Monotherapy in Subjects with Early Parkinson Prof. Wong Ka Sing Lawrence
2011.599 An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn Dr Ng Siew Chien
2021.535 An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Prof. Li Chi Kong
2019.481 AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF REGN3918 IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA Dr. WONG Raymond Siu Ming
2021.567 An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in study participants with persistent or chronic primary immune thrombocytopenia (ITP) Dr. WONG Raymond Siu Ming
王紹明
2002.411 An Open-Label Extension Trial to Assess The Safety of Galantamine HBr in the Treatment of Vascular Dementia Revised : cre-2002.216-t, cre-2002.124-t Prof. Wong Ka Sing Lawrence
2005.300 An Open-Label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 80mg + Hydrochlorothiazide 25mg tablets Alone or in Combination with Other Antihypertensive Medications in Patients with Hypertension Prof. Kong Pik Shan Alice
2011.562 An Open-Label Long-term Safety Extension Trial for Subjects with Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC) Professor Tam Lai-Shan
2011.028 An open-label multi-center study of erlotinib (Tarceva®) as first line therapy until and beyond RECIST progression in NSCLC patients who harbor EGFR mutations Prof. MOK Tony Shu Kam
2010.158 An Open-Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures Dr. Kwan Patrick
2005.197 An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL_/CAELYX_ and YONDELIS Prof. Yeo Winnie
2007.247 An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women with Advanced or Metastatic Breast Cancer Prof. Yeo Winnie
2024.724 An Open-Label Phase 1/2 Study of WGI-0301 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma as Second Line Therapy Prof. CHAN Stephen Lam
陳林
2023.312 An Open-Label Phase 1b Study Evaluating the Safety, Tolerability, Immunogenicity and Antiviral Activity of Multiple Doses of CLB-3000 in Subjects with Chronic Hepatitis B Prof. WONG Grace
2007.241 An Open-Label Phase I/II Study to Assess the Safety and Immunogenicity of Two Doses of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Volunteers Aged 21 to 45 Years Prof. Hui SC David
2016.165 An open-label phase II study of pembrolizumab in East Asian patients with advanced/metastatic acral lentiginous melanoma Dr. LOONG Herbert
龍浩鋒
2010.457 An Open-label Phase Ii Study of TK1258 as Neo-adjuvant Therapy in Patient with Muscle-invasive Bladder Cancer Dr Chan Shu Yin Eddie
2002.394 An Open-Label Phase IIa Trial of Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients with Advanced Local or Metastatic Gastric Cancer Prof. Yeo Winnie
2018.444 An open-label pilot study of fecal microbiota transplant (FMT) to induce weight loss in obese subjects Prof. NG Siew Chien
黃秀娟教授
2007.242 An Open-Label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects with Schizophrenia Dr. Chung Wai Sau Dicky
2021.134 An open-label randomized controlled trial on convalescent plasma for treatment of severe COVID-19 infection Dr. LUI Grace C.Y.
雷頌恩
2015.607 An Open-label Randomized Multinational Phase 3 Trial of Nivolumab versus Docetaxel in Previously Treated Subjects with Advanced or Metastatic Non-small Cell Lung Cancer Prof. MOK Tony Shu Kam
莫樹錦
2003.230 An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) ("XELOX") versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin with Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") as First-Line Treatment for Patients with Metastatic Colorectal Cancer Prof. Chan Tak Cheung Anthony
2019.704 An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis Prof. LI Chi Kong
李志光教授
2017.568 An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma Prof. LI Chi Kong
李志光教授
2007.361 An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) Dr. LI Chi Kong
2012.034 An Open-label study to investigate Deep Brain Stimulation over ventral capsule/ventral striatum area in the treatment of Resistant Obsessive Compulsive Disorder Prof. POON Wai Sang
2010.255 An Open-label study to investigate Deep Brain Stimulation over verntal capsule/ventral striatum area in the treatment of Treatment Resistant Major Depressive Disorder Prof. Wing Yun Kwok
2012.357 An open-label trial of 48-week peginterferon alfa-2a (PEGASYS) to assess the sustained response of chronic hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy Prof. WONG Grace Lai Hung
2013.016 An open-label trial of 48-week peginterferon alfa-2a (PEGASYS) to assess the sustained response of chronic hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy Dr. Chan Kam Hon
2012.539 An open-label trial of 48-week peginterferon alfa-2a (PGEASYS) to assess the sustained response of chroinc hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy Dr. HUI Aric Josun
2002.459 An Open-label, Long-term, Flexible-dose Study of Safety, Tolerability, and Therapeutic Response of PNU-95666E in Patients with Parkinson's Disease Prof. Wong Ka Sing Lawrence
2025.180 An Open-label, Multi-center Phase II Study of Durvalumab and Tremelimumab with Lenvatinib as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma Prof. CHAN Stephen Lam
2019.684 An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments Prof. MA Brigette Buig Yue
馬碧如教授
2019.453 An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib Dr. LOONG Herbert Ho Fung
龍浩鋒醫生
2012.451 An Open-Label, Multi-Center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed Influenza Infection Professor Leung Ting Fan

Page 62 of 289.